Cullgen Revenue and Competitors
Estimated Revenue & Valuation
- Cullgen's estimated annual revenue is currently $2.7M per year.
- Cullgen's estimated revenue per employee is $93,534
- Cullgen's total funding is $121M.
Employee Data
- Cullgen has 29 Employees.
- Cullgen grew their employee count by -6% last year.
Cullgen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Assistant Director | Reveal Email/Phone |
3 | Medical Director | Reveal Email/Phone |
Cullgen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 4 | -50% | N/A | N/A |
#6 | $0.7M | 8 | 0% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 17 | 31% | N/A | N/A |
What Is Cullgen?
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
keywords:N/A
$121M
Total Funding
29
Number of Employees
$2.7M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cullgen News
Q3: What is Cullgen's PROTAC drug pipeline and also IPO status? A3: You will start seeing more IND's from Cullgen this year. We expect 2-3 IND's...
... Casma Therapeutics; Celeris Therapeutics; Centessa Pharmaceuticals; Coho Therapeutics; ComInnex; Cullgen; Cullinan Oncology; Dalriada...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11M | 29 | -58% | N/A |
#2 | $2M | 29 | 7% | $6.9M |
#3 | $4.9M | 29 | -6% | N/A |
#4 | $8.4M | 29 | -29% | N/A |
#5 | $1.7M | 29 | -3% | N/A |